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Quality of Life Assessment in Vascular Disease: Towards a 
Consensus 
D. K. Beattie*, J. Golledge, R. M. Greenhalgh and A. H. Davies 
Charing Cross and Westminster Medical School, London W6 8RF U.K. 
Objectives: To review the assessment ofquality of life in vascular disease, with particular eference to the Nottingham 
Health Profile and Medical Outcomes Study Short Form 36. 
Design and methods: A detailed literature search of relevant publications. Trans-national and trans-cultural convergence 
and validity of these scales were assessed. 
Results: The Short Form 36 was found to be the most valid and reliable quality of life measure for use in an international 
vascular setting. 
Conclusion: In the absence of a specific dedicated vascular disease quality of life measure, the Medical Outcomes Study 
Short Form 36 should be used as a quality of life measure in the assessment of vascular disease in an international 
setting. 
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Introduction 
In order to investigate the need for, and efficacy of, 
vascular intervention, a measure for assessment and 
resultant outcome is necessary. This assessment 
should be qualitative as well as quantitative and there 
are therefore three measures of treatment: cost, sur- 
vival and quality of life. The first two of these are 
absolute and hence relatively easy to measure, but an 
assessment of quality of life is complex. This is due to 
the large number of variables which need to be 
considered to gain an overall score, these including 
psychosocial aspects, functional measures and, in 
vascular disease, morbidity end-points uch as stroke, 
amputation and ulcer healing. The measurement of
quality of life is thus difficult and important in 
assessing both the need for, and effect of, vascular 
intervention, and it is desirable that this measure be 
standardised across geographical nd cultural bound- 
aries and patient groups. Only thus will comparisons 
between different populations be valid. 
*Please address all correspondence to: Mr. Beattie, Department of 
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That no single quality of life tool fulfils the above 
criteria is evident from the number of generic scales 
available. Much vascular surgery is performed to 
improve or sustain quality of life, and treatment 
analysis is increasingly conducted in an international 
arena; the concept of "managed care" in the U.S. has 
made measurement of quality of life particularly 
relevant. Increasingly trials are multinational and 
adoption of a single measure of quality of life would 
The Ideal Quality of Life Measure 
The ideal quality of life measure is one that could be 
used with equal validity by all healthcare personnel, 
in any setting or location, in the assessment of any 
disease or treatment. The criteria for such a quality of 
life measure are therefore that: 
- - I t  should be equally applicable to any disease 
process or outcome. 
- - I t  should be equally applicable across all levels of 
illness and degrees of invalidity. 
- - I t  should be of proven validity, with a high level of 
convergence within patient groups, when applied 
across geographic, linguistic and cultural 
boundaries. 
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allow comparison of outcomes, whatever the geo- 
graphical lingual or temporal separation, with 
validity. 
Disease Specific and Generic Instruments 
There are two approaches to quality of life measure- 
ment: generic instruments which summarise health 
related quality of life (HRQL) and disease specific 
tools which focus on single diseases or groups. 
The principle advantages of generic tools are their 
availability "off-the-shelf", suitability in a wide vari- 
ety of areas and populations and ability to broadly 
compare the effects of treatment programmes. Con- 
versely they may be less responsive than disease 
specific tools, registering response only if the changes 
are large, missing subtle differences. 
Disease specific tools focus on aspects of health 
related to their designated disease area. They may be 
much more sensitive to change, though comparison 
with some generic scales has shown exceptions. 
Examples include the European Research and Treat- 
ment of Cancer (EORTC) Quality of Life Ques- 
tionnaire, 1 the Spitzer Quality of Life Index for 
Cancer, 2the Diabetes Quality of Life Measure 3 and the 
Inflammatory Bowel Disease Questionnaire. 4 A new 
addition is the Gastrointestinal Quality of Life Index, 
now ready for clinical and research use. 5 
The validation of any one model in a number of 
languages is not the only factor in favour of its 
selection. The most important consideration i  recom- 
mending a scale for use internationally in vascular 
disease is that it should detect hose components of 
quality of life relevant to vascular disease i.e. prefera- 
bly have been designed with vascular use in mind. 
Translational validity would then be a secondary, 
though still important, consideration. Todate, no such 
dedicated vascular-specific tool exists, and thus whilst 
it is important that an adopted scale be that which best 
fits vascular disease, this secondary consideration 
assumes greater importance. 
The most used generic scales are the Medical 
Outcomes Study (MOS) 36-item short form health 
survey (SF-36), for example in varicose veins 6 and the 
treatment of intermittent claudication, 7 and the Not- 
tingham Health Profile (NHP) in amputations s and 
venous ulceration; 9 indeed peripheral arterial disease 
was used in the repeatability validation of the NHP as 
it is relatively stable. A single generic measure of 
quality of life adopted for sole use in vascular disease 
would likely be one of these. Both are reviewed in 
detail with mention of some of the other scales 
available. 
Review of Common Generic Quality of Life 
Measures 
The Sickness Impact Profile 1° has been translated to 
seven languages, ~1though reliability and validity 
within these is not well assessed, 12but it correlates 
poorly with clinical status. 13 It is also less sensitive to 
functional improvements than deteriorations. 14 Euro- 
Qol was developed for use in England, Holland and 
Scandinavia, but for use with other HRQL measures. ~5
The functional scales within it are disadvantaged by a 
large ceiling effect ~6 decreasing its discriminatory 
power for small changes. The Dartmouth COOP 
Function Charts were developed for a clinical set- 
ting, ~7 but exclude disability and have low correlation 
with clinical status indicators. ~8 They have, however, 
formed the basis of an international system of func- 
tional assessment, ~9 albeit with little evidence of 
translational validity thus far. The Patient Generated 
Index 2° is a recent scale based on the concept hat to 
improve quality of life means to "narrow the gap 
between patient hopes and expectations and what is 
experienced". It has potential in clinical use but much 
validation work remains. The London Handicap 
Scale 21 has proven reliable but is valid for use only in 
groups. 
The Rosser Classification 22 was developed in the 
1970s for hospital use by observer rating. To overcome 
this potential disadvantage the self-rated Health 
Measurement Questionnaire was devised. 23 Little vali- 
dation of this has been reported. The Quality of Well 
Being Scale provides anumerical point in-time expres- 
sion of well-being 24 and has good validity as a general 
health outcome measure and in different populations. 
It has not been extensively translated. Finally, the 
McMaster Health Index Questionnaire has been 
widely used and appears sensitive to change and 
effective in several modes of administration. 25 Again 
however little international work has been done. This 
list of scales is by no means exhaustive. 
The Nottingham Health Profile (NHP) 1981 
The NHP was derived from the Nottingham Health 
Index to measure perceived stress in relation to 
potentially disabling health conditions 26and assess 
factors predicting the need for health care. It has two 
parts. Part 1 is the larger with 38 items in six domains 
- -  pain, energy, emotion, sleep, social isolation and 
physical ability. The lack of a continuum within some 
of the scales is controversial, limiting sensitivity in 
detecting a small clinical improvement from complete 
to partial dependence. 
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Part 2 explores the impact of illness on everyday life 
in seven areas - -  work, sex, interests and hobbies, 
home maintenance, social life and holidays. The test 
takes 15 minutes and can be self administered. 
The NHP has been widely used in varying disease 
types and severity, and separates extremes of severe 
from non-severe illness, 27 though may not adequately 
measure distress, range of function and change due to 
medical intervention. The responsiveness of NHP has 
also been questioned, being confirmed in cardiac 
transplantation 28 but not in minor surgery with 
respect o mild levels of pain, emotional distress and 
general health perceptions. 29The main limitation on 
sensitivity of the NHP is its large floor effect; many 
with mild symptoms will register as having none. 
Registration of a disease free state cannot be assured, B° 
and small improvements may not be detected. 
As a measure of distress in physical and psychoso- 
cial functioning related to chronic disease and major 
illness, the NHP is a valuable resource for adaptation 
to an international HRQL role. ~2 However, although 
often used as such, it was not intended to measure 
HRQL in general population samples, 27 nor to detect 
states of mild symptom severity. 31 
NHP has, or is being, adapted to Swedish, French, 
Spanish, Italian, German, Finnish and Danish, and 
some work on validation has been done. In French, 
variations in perceived severity of items were found 
for all NHP dimensions. Validity and reliability were 
not recorded, B2 as with the Dutch version. Investiga- 
tion of the Spanish version in end stage renal disease 
found that it is sufficiently reliable for all sub-groups, 
providing a "realistic approximation to the reliability 
of the questionnaire in actual research and clinical 
applications'. BBThe version has been validated to a 
degree by correlation with levels of self reported 
health and clinically assessed isease severity. 
The Swedish version is the most used and best 
evaluated of all NHP derivations. Tests in relation to 
arthritis showed adequate reliability. B4 Validity was 
shown by its ability to discriminate well being in 
normotensives from hypertensives when compared to 
other scales. 3~ With asthma however NHP did not 
detect moderate improvements in emotional state, life 
satisfaction and somatic problems found with other 
HRQL measures. B6
The NHP has been effectively applied to vascular 
disease, 8'9 though the SF-36 may be more sensitive to 
minor disability levels. ~6 It has been translated with 
precision but confirmation of how well different 
methods of data collection compare internationally is
lacking. Equivalence of construction between versions 
is poorly demonstrated and much work is required to 
appraise the international future of the NHP. 
The NHP performs well within its defined remit 
and, despite its limitations, is a valid contender for use 
in a vascular HRQL role. Major criticisms, however, 
are its perceived inferior sensitivity compared to SF-36 
and the lack of evidence that it has translated well  
despite encouraging early reports. 
Medical Outcomes Study (MOS) 36 Item Short 
Form Health Survey (SF-36) 
The original MOS HRQL survey had eight domains 
and the short form aimed to closely replicate this, 
taking 36 items from these. B7 It combined some scales 
from the full length MOS measure with items from the 
earlier MOS 20 item format. The SF-36 can be self 
administered in 10 minutes and has been validated 
against clinically defined groups and the long form 
versions of the MOS scales. B8 Importantl)~ the scales 
adequately separate well-being from minor and major 
illness; stages and severity of disease, and moderate 
treatment effects are identified. 
The SF-36 does have limitations. The bodilYsPain 
scale is poorly convergent with known groups B and 
functional impairment is only moderately conver- 
gent. B9 There are floor effects in role functioning in 
severely ill patients 4° for whom deterioration in 
function may not register. The physical activity items 
measure activities such as walking or kneeling, 
excluding integrated activities uch as cooking, driv- 
ing and ironing. 
The SF-36 is a carefully designed instrument of 
HRQL measurement and within a year of publication 
was being used in 200 trials. Despite this there is 
considerable debate as to its application and validity. 
Brazier et al. 16 tested its acceptability and validity and 
found it to be superior to existing general health 
questionnaires. When compared to the NHP each 
respondent completed more of the survey. Internal 
consistency was confirmed and test-retest reliability 
was "excellent". Evidence for construct reliability was 
"substantial". The comparison supported the oft made 
criticism of the NHP that it is insensitive for defining 
health improvements in a general population. The SF- 
36 was much superior, finding patients with minor 
degrees of impairment regarded as unaffected by 
NHP. There was criticism of the comparison however. 
Firstly, some felt it inappropriate as the scales measure 
different concepts. In addition the claim that the test- 
retest rates were excellent was challenged. 4~'42 It was 
countered that the NHP was often used in the manner 
in which it had been compared and that the instru- 
ment, being well established, was the obvious choice 
for comparison. 4B
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Further studies have supported the SF-36. 44'45 When 
assessed with respect to validity, reliability and accept- 
ability in four conditions, including varicose veins, 
response rate was high and the test met rigorous 
criteria for reliability and internal consistency. 6 How- 
ever its sensitivity to changes in health status over 
time must be tested. When compared to a specific 
diabetes scale SF-36 provided more information 
regarding functional status. 3 It is thus a well validated 
scale applicable to many areas, including46vascular 
disease, as in a recent study in claudicants. 
The ability to measure small changes across inter- 
national boundaries using a scale which is equally 
applicable and valid in all is vital. Whilst some work 
has been done with the NHP in a number of languages 
in this respect, the SF-36 is in a far stronger position. 
The International Quality of Life Assessment (IQOLA) 
project 47 is a 4 year project o translate and adapt the 
SF-36 questionnaire in 15 countries. Translations will 
be validated and documented for use in international 
studies of health outcomes. The project will also 
validate psychometrically based physical and mental 
health summary scores, as well as health utility 
indices incorporating SF-36 scales for use in cost- 
utility and resource allocation studies. 
Summary 
A number of different health related quality of life 
measures have been listed in this paper, with the SF-36 
and NHP being reviewed in detail, and the ideal 
quality of life tool has been defined. No generic scale 
fits all criteria, particularly regarding validity and 
convergence between patient groups, geographic 
boundaries and degrees of illness, most being inade- 
quate due to lack of data outside the country of 
origin. 
The concept of a single quality of life scale for 
vascular disease is an attractive one; only thus will 
valid comparisons of work by different investigators 
be possible. Standard HRQL measures can be applied 
to vascular patients, though the lack of a validated 
weighting system may make them of little use in 
producing values of cost-effectiveness or decision 
analysis. 4s It has been suggested that vascular specific 
societies should "set up an international working 
group...to address clinical outcomes, research and 
patient monitoring...'.49 The current lack of a specific 
tool however means that a generic tool must be 
adopted, and the obvious candidates are the NHP and 
SF-36. 
The SF-36 has a number of advantages over the 
NHP. It is widely accepted and is more sensitive to 
some levels of disease. Undoubtedly, however, its 
strongest claim is the IQOLA project which will see it 
validated in all major languages, making it a truly 
international scale of health related quality of life. It 
seems likely that it will be adopted as such and it is 
thus that the MOS SF-36 health related questionnaire 
can be recommended for use in vascular disease- 
related HRQL assessments and outcome analyses. 
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